---
document_datetime: 2025-10-08 10:41:03
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tecvayli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tecvayli-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7193858
conversion_datetime: 2025-12-31 07:47:54.788803
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tecvayli

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a variation | 04/09/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000278107                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |            |            |             |                 |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------|
| Variation type IB / EMA/VR/0000273943 | B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/06/2025 | N/A        |             |                 |
| Variation type II / EMA/VR/0000254941 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.4 of the SmPC in order                                                                                                                                                                                                                                                                                                                                                         | 12/06/2025 | 12/08/2025 | SmPC and PL | Not applicable. |

<div style=\"page-break-after: always\"></div>

|                                       | to include the term 'fatal' under the warning for Neurologic Toxicities, including ICANS. In addition, the MAH took the opportunity to introduce minor changes to section 4.2 of the SmPC in order to update the intervals regarding the restarting of teclistamab after a dose delay. Furthermore, the MAH took the opportunity to update the PI with the excipient information on polysorbate following the latest EU Excipients Guideline as well as to update the list of local representatives in the Package Leaflet.   |            |     |                                                                                                                      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000272928 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted To extend the due date of the interim report for study 64007957MMY3001 from September 2025 to March 2026 in the RMP.                                                                                                                                                              | 03/06/2025 | N/A | To extend the due date of the interim report for study 64007957MMY3001 from September 2025 to March 2026 in the RMP. |
| Variation type IA / EMA/VR/0000272695 | B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.a Change in the name of a supplier of a packaging component. If the information is not needed in the dossier CMDh recommends deletion of this information. - Accepted                                                                                                                                                                                                                                               | 22/05/2025 | N/A |                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.e.7 Change in supplier of packaging components or devices (when mentioned in the dossier) - B.II.e.7.a Change in the name of a supplier of a packaging component. If the information is not needed in the dossier CMDh recommends deletion of this information. - Accepted   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/0000249306   | - Renewal - Accepted                                                                                                                                                                                                                                                              | 25/04/2025 | 12/08/2025 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Tecvayli, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| Variation type IB / EMA/VR/0000263112 | B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.z Other variation - Accepted                                                                                                                                                                       | 24/04/2025 | N/A        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUR / EMA/PSUR/0000274444            | - -                                                                                                                                                                                                                                                                               |            |            | Maintenance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |